

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

February 08, 2013

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Kind Attn.: Mr. K. K. Mishra

Dear Sirs


Re.: Unaudited financial results for the quarter/nine months ended on December 31, 2012.

We are forwarding herewith unaudited financial results for the quarter/nine months ended on December 31, 2012 reviewed by Audit Committee and taken on record by the Board of Directors on February 08, 2013 pursuant to Clause 41 of the Listing Agreement; the same may please receive in order.

Thanking you

Yours faithfully

For **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH

COMPANY SECRETARY

Encl.: As above

PART I
Unaudited [Provisional] Financial Results for the Quarter and Nine Months ended December 31, 2012.

Rupees in Lacs						Sr. No.	Particulars	Rupees in Lacs					
CONSOLIDATED								COMPANY					
3 Months ended 31/12/2012	Preceding 3 months ended 30/09/2012	Corresponding 3 months ended 31/12/2011 in the previous year	Year to date figures for the current period ended 31/12/2012	Year to date figures for the previous year ended 31/12/2011	Previous year ended 31/03/2012			3 Months ended 31/12/2012	Preceding 3 months ended 30/09/2012	Corresponding 3 months ended 31/12/2011 in the previous year	Year to date figures for the current period ended 31/12/2012	Year to date figures for the previous year ended 31/12/2011	Previous year ended 31/03/2012
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
159,420	154,469	137,364	468,553	380,141	518,067	1	Income from operations	66,191	63,940	66,434	193,382	185,091	245,650
3,318	3,219	2,118	9,591	5,580	9,070	i	Gross Sales	1,416	1,617	1,148	4,155	3,052	4,325
156,102	151,250	135,246	458,962	374,561	508,997	ii	Less: Excise Duty	64,775	62,323	65,286	189,227	182,039	241,325
4,309	3,514	3,076	15,655	11,970	17,334	a	Net Sales	13,645	17,161	16,176	51,799	54,661	73,753
160,411	154,764	138,322	474,617	386,531	526,331	b	Other operating income	78,420	79,484	81,462	241,026	236,700	315,078
						c	Total income from operations (net)						
39,845	38,817	24,901	109,863	84,419	118,894	2	Expenses	23,188	23,312	18,082	63,934	56,562	79,094
19,879	22,700	29,028	59,680	56,735	67,852	a	Cost of materials consumed	6,411	7,005	11,198	17,806	25,229	30,455
(5,932)	(4,406)	(8,728)	(7,304)	(20,695)	(18,811)	b	Purchases of stock-in-trade	(2,331)	(1,617)	(2,557)	(242)	(5,880)	(5,849)
23,194	22,830	20,322	69,000	56,180	75,122	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	12,397	12,826	11,237	37,928	32,625	43,455
4,961	4,323	4,654	13,627	11,880	15,788	d	Employee benefits expense	3,127	2,672	2,686	8,551	7,937	10,823
57,925	51,760	46,640	159,074	129,787	174,888	e	Depreciation and amortisation expense	30,694	28,409	29,856	83,718	79,550	101,145
						f	Other expenses	73,486	72,607	70,502	211,695	196,023	259,123
139,872	136,024	116,817	403,940	318,306	433,733	g	Total expenses	4,934	6,877	10,960	29,331	40,677	55,955
20,539	18,740	21,505	70,677	68,225	92,598	3	Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	1,502	5,202	6,431	6,973	22,706	23,914
1,706	646	1,822	3,303	3,557	5,315	4	Other income	6,436	12,079	17,391	36,304	63,383	79,869
22,245	19,386	23,327	73,980	71,782	97,913	5	Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	3,020	2,794	4,430	9,683	11,091	12,826
4,789	4,050	5,935	14,558	14,736	18,490	6	Finance costs	3,416	9,285	12,961	26,621	52,292	67,043
17,456	15,336	17,392	59,422	57,046	79,423	7	Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	0	0	0	0	0	0
0	0	0	0	0	0	8	Exceptional items	3,416	9,285	12,961	26,621	52,292	67,043
17,456	15,336	17,392	59,422	57,046	79,423	9	Profit/ (Loss) from ordinary activities before tax (7+8)	20	(460)	(460)	210	480	1,291
6,303	4,939	1,736	17,779	6,941	11,304	10	Tax expense	3,396	9,745	13,421	26,411	51,812	65,752
11,153	10,397	15,656	41,643	50,105	68,119	11	Net Profit/ (Loss) from ordinary activities after tax (9-10)	0	0	0	0	0	0
0	0	0	0	0	0	12	Extraordinary items (net of tax expense)	3,396	9,745	13,421	26,411	51,812	65,752
11,153	10,397	15,656	41,643	50,105	68,119	13	Net Profit/ (Loss) for the period (11+12)	0	0	0	0	0	0
0	0	0	0	0	0	14	Share of profit/ (loss) of associates	0	0	0	0	0	0
(862)	(883)	(735)	(2,359)	(1,934)	(2,860)	15	Minority interest	3,396	9,745	13,421	26,411	51,812	65,752
10,291	9,514	14,921	39,284	48,171	65,259	16	Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	10,237	10,237	10,237	10,237	10,237	10,237
10,237	10,237	10,237	10,237	10,237	10,237	17	Paid-up equity share capital (Face Value Rs. 5/-)						
					247,122	18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						244,695
						19	Earnings per share (before extraordinary items)						
5.03	4.65	7.29	19.19	23.53	31.87	i	(of Rs. 5/- each) (not annualised):	1.66	4.76	6.55	12.90	25.31	32.11
5.03	4.65	7.29	19.19	23.53	31.87	a	Basic (Rs.)	1.66	4.76	6.55	12.90	25.31	32.11
						b	Diluted (Rs.)						
5.03	4.65	7.29	19.19	23.53	31.87	19	Earnings per share (after extraordinary items)						
5.03	4.65	7.29	19.19	23.53	31.87	ii	(of Rs. 5/- each) (not annualised):	1.66	4.76	6.55	12.90	25.31	32.11
						a	Basic (Rs.)	1.66	4.76	6.55	12.90	25.31	32.11
						b	Diluted (Rs.)	1.66	4.76	6.55	12.90	25.31	32.11

Notes :

- The above results for the quarter/ nine months ended on December 31, 2012 were reviewed by the Audit Committee on February 7, 2013 and then approved by the Board of Directors at their meeting held on February 8, 2013.
- The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Clause 41 of the Listing Agreement.
- The changes in Investments during the quarter are as under:
ZyduS BSV Pharma Private Limited [Additional Investment] - Rs. 200 Lacs
ZyduS International Private Limited, Ireland [Additional Investment] - Rs. 1,356 Lacs
- Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the current reporting period.
- The Company has one segment of activity viz., "Pharmaceuticals".

PART II

Select information for the Quarter and Nine Months Ended 31/12/2012

3 Months ended 31/12/2012	Preceding 3 months ended 30/09/2012	Corresponding 3 months ended 31/12/2011 in the previous year	Year to date figures for the current period ended 31/12/2012	Year to date figures for the previous year ended 31/12/2011	Previous year ended 31/03/2012	Particulars	3 Months ended 31/12/2012	Preceding 3 months ended 30/09/2012	Corresponding 3 months ended 31/12/2011 in the previous year	Year to date figures for the current period ended 31/12/2012	Year to date figures for the previous year ended 31/12/2011	Previous year ended 31/03/2012
51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	A 1 PARTICULARS OF SHAREHOLDING Public shareholding - Number of shares - Percentage of Shareholding	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%
Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	2 Promoters and Promoter Group Shareholding a Pledged / Encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.
153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	b Non - encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of Promoter and Promoter group) - Percentage of shares (as a % of the total share capital of the company)	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%	153,138,046 100.00% 74.79%

Particulars	3 months ended 31/12/2012
B INVESTOR COMPLAINTS [In Numbers]	
Pending at the beginning of the quarter	Nil
Received during the quarter	8
Disposed of during the quarter	8
Remaining unresolved at the end of the quarter	Nil

Ahmedabad, February 8, 2013

For Cadila Healthcare Limited,


 Pankaj R. Patel
 Chairman & Managing Director